0000000000930276

AUTHOR

Edo Richard

showing 3 related works from this author

Primary stroke prevention worldwide:translating evidence into action

2021

Abstract: Stroke is the second leading cause of death and the third leading cause of disability worldwide and its burden is increasing rapidly in low-income and middle-income countries, many of which are unable to face the challenges it imposes. In this Health Policy paper on primary stroke prevention, we provide an overview of the current situation regarding primary prevention services, estimate the cost of stroke and stroke prevention, and identify deficiencies in existing guidelines and gaps in primary prevention. We also offer a set of pragmatic solutions for implementation of primary stroke prevention, with an emphasis on the role of governments and population-wide strategies, includin…

Global Burden of Disease03 medical and health sciences0302 clinical medicineNursingBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Neurology.Medicine030212 general & internal medicineStrokeHealth policyCause of deathEntire populationHealth professionalsbusiness.industryHealth PolicyPublic Health Environmental and Occupational HealthBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Neurologija.medicine.disease3. Good healthStrokeAction (philosophy)Stroke preventionOcclusive Cerebrovascular DiseaseLife course approachHuman medicinebusiness030217 neurology & neurosurgery
researchProduct

Investigation of antihypertensive class, dementia, and cognitive decline: a meta-analysis

2020

ObjectiveHigh blood pressure is one of the main modifiable risk factors for dementia. However, there is conflicting evidence regarding the best antihypertensive class for optimizing cognition. Our objective was to determine whether any particular antihypertensive class was associated with a reduced risk of cognitive decline or dementia using comprehensive meta-analysis including reanalysis of original participant data.MethodsTo identify suitable studies, MEDLINE, Embase, and PsycINFO and preexisting study consortia were searched from inception to December 2017. Authors of prospective longitudinal human studies or trials of antihypertensives were contacted for data sharing and collaboration.…

GerontologyMaleLATE-LIFEMEDLINEBLOOD-PRESSUREPsycINFOArticleELDERLY-PEOPLE03 medical and health sciences0302 clinical medicinehoitomenetelmätkohonnut verenpainemedicineDementiaHumansDRUGSCognitive Dysfunction030212 general & internal medicineCognitive declineHEALTHYAntihypertensive AgentsAgedMETABOLIC SYNDROMEAged 80 and overRISKbusiness.industrymeta-analyysiCognitionINCIDENT DEMENTIAMiddle Aged16. Peace & justicemedicine.diseaseDisorders of movement Donders Center for Medical Neuroscience [Radboudumc 3]PREVENTION3. Good healthClinical trialSystematic reviewMeta-analysisHypertensionCOHORT PROFILE[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieDementiaFemaleNeurology (clinical)OLDbusiness030217 neurology & neurosurgerydementia
researchProduct

An investigation of antihypertensive class, dementia, and cognitive decline

2019

Objective High blood pressure is one of the main modifiable risk factors for dementia. However, there is conflicting evidence regarding the best antihypertensive class for optimising cognition. Our objective was to determine whether any particular class of antihypertensive was associated with a reduced risk of cognitive decline or dementia using comprehensive meta-analysis including reanalysis of original participant data. Methods To identify suitable studies MEDLINE, Embase and PsycINFO® and pre-existing study consortia were searched from inception to December 2017. Authors of prospective longitudinal human studies or trials of antihypertensives were contacted for data-sharing and collabor…

TansleyBlood pressureDementiaAntihypertensive
researchProduct